-
Joining Forces for Pathology Diagnostics with AI Assistance: The EMPAIA Initiative
Authors:
Norman Zerbe,
Lars Ole Schwen,
Christian Geißler,
Katja Wiesemann,
Tom Bisson,
Peter Boor,
Rita Carvalho,
Michael Franz,
Christoph Jansen,
Tim-Rasmus Kiehl,
Björn Lindequist,
Nora Charlotte Pohlan,
Sarah Schmell,
Klaus Strohmenger,
Falk Zakrzewski,
Markus Plass,
Michael Takla,
Tobias Küster,
André Homeyer,
Peter Hufnagl
Abstract:
Over the past decade, artificial intelligence (AI) methods in pathology have advanced substantially. However, integration into routine clinical practice has been slow due to numerous challenges, including technical and regulatory hurdles in translating research results into clinical diagnostic products and the lack of standardized interfaces. The open and vendor-neutral EMPAIA initiative addresses…
▽ More
Over the past decade, artificial intelligence (AI) methods in pathology have advanced substantially. However, integration into routine clinical practice has been slow due to numerous challenges, including technical and regulatory hurdles in translating research results into clinical diagnostic products and the lack of standardized interfaces. The open and vendor-neutral EMPAIA initiative addresses these challenges. Here, we provide an overview of EMPAIA's achievements and lessons learned. EMPAIA integrates various stakeholders of the pathology AI ecosystem, i.e., pathologists, computer scientists, and industry. In close collaboration, we developed technical interoperability standards, recommendations for AI testing and product development, and explainability methods. We implemented the modular and open-source EMPAIA platform and successfully integrated 14 AI-based image analysis apps from 8 different vendors, demonstrating how different apps can use a single standardized interface. We prioritized requirements and evaluated the use of AI in real clinical settings with 14 different pathology laboratories in Europe and Asia. In addition to technical developments, we created a forum for all stakeholders to share information and experiences on digital pathology and AI. Commercial, clinical, and academic stakeholders can now adopt EMPAIA's common open-source interfaces, providing a unique opportunity for large-scale standardization and streamlining of processes. Further efforts are needed to effectively and broadly establish AI assistance in routine laboratory use. To this end, a sustainable infrastructure, the non-profit association EMPAIA International, has been established to continue standardization and support broad implementation and advocacy for an AI-assisted digital pathology future.
△ Less
Submitted 16 April, 2024; v1 submitted 22 December, 2023;
originally announced January 2024.
-
Recommendations on test datasets for evaluating AI solutions in pathology
Authors:
André Homeyer,
Christian Geißler,
Lars Ole Schwen,
Falk Zakrzewski,
Theodore Evans,
Klaus Strohmenger,
Max Westphal,
Roman David Bülow,
Michaela Kargl,
Aray Karjauv,
Isidre Munné-Bertran,
Carl Orge Retzlaff,
Adrià Romero-López,
Tomasz Sołtysiński,
Markus Plass,
Rita Carvalho,
Peter Steinbach,
Yu-Chia Lan,
Nassim Bouteldja,
David Haber,
Mateo Rojas-Carulla,
Alireza Vafaei Sadr,
Matthias Kraft,
Daniel Krüger,
Rutger Fick
, et al. (5 additional authors not shown)
Abstract:
Artificial intelligence (AI) solutions that automatically extract information from digital histology images have shown great promise for improving pathological diagnosis. Prior to routine use, it is important to evaluate their predictive performance and obtain regulatory approval. This assessment requires appropriate test datasets. However, compiling such datasets is challenging and specific recom…
▽ More
Artificial intelligence (AI) solutions that automatically extract information from digital histology images have shown great promise for improving pathological diagnosis. Prior to routine use, it is important to evaluate their predictive performance and obtain regulatory approval. This assessment requires appropriate test datasets. However, compiling such datasets is challenging and specific recommendations are missing.
A committee of various stakeholders, including commercial AI developers, pathologists, and researchers, discussed key aspects and conducted extensive literature reviews on test datasets in pathology. Here, we summarize the results and derive general recommendations for the collection of test datasets.
We address several questions: Which and how many images are needed? How to deal with low-prevalence subsets? How can potential bias be detected? How should datasets be reported? What are the regulatory requirements in different countries?
The recommendations are intended to help AI developers demonstrate the utility of their products and to help regulatory agencies and end users verify reported performance measures. Further research is needed to formulate criteria for sufficiently representative test datasets so that AI solutions can operate with less user intervention and better support diagnostic workflows in the future.
△ Less
Submitted 21 April, 2022;
originally announced April 2022.
-
An interpretable automated detection system for FISH-based HER2 oncogene amplification testing in histo-pathological routine images of breast and gastric cancer diagnostics
Authors:
Sarah Schmell,
Falk Zakrzewski,
Walter de Back,
Martin Weigert,
Uwe Schmidt,
Torsten Wenke,
Silke Zeugner,
Robert Mantey,
Christian Sperling,
Ingo Roeder,
Pia Hoenscheid,
Daniela Aust,
Gustavo Baretton
Abstract:
Histo-pathological diagnostics are an inherent part of the everyday work but are particularly laborious and associated with time-consuming manual analysis of image data. In order to cope with the increasing diagnostic case numbers due to the current growth and demographic change of the global population and the progress in personalized medicine, pathologists ask for assistance. Profiting from digi…
▽ More
Histo-pathological diagnostics are an inherent part of the everyday work but are particularly laborious and associated with time-consuming manual analysis of image data. In order to cope with the increasing diagnostic case numbers due to the current growth and demographic change of the global population and the progress in personalized medicine, pathologists ask for assistance. Profiting from digital pathology and the use of artificial intelligence, individual solutions can be offered (e.g. detect labeled cancer tissue sections). The testing of the human epidermal growth factor receptor 2 (HER2) oncogene amplification status via fluorescence in situ hybridization (FISH) is recommended for breast and gastric cancer diagnostics and is regularly performed at clinics. Here, we develop an interpretable, deep learning (DL)-based pipeline which automates the evaluation of FISH images with respect to HER2 gene amplification testing. It mimics the pathological assessment and relies on the detection and localization of interphase nuclei based on instance segmentation networks. Furthermore, it localizes and classifies fluorescence signals within each nucleus with the help of image classification and object detection convolutional neural networks (CNNs). Finally, the pipeline classifies the whole image regarding its HER2 amplification status. The visualization of pixels on which the networks' decision occurs, complements an essential part to enable interpretability by pathologists.
△ Less
Submitted 25 May, 2020;
originally announced May 2020.
